Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation

Gruss, Claudia; Geißler, A.; Schalke, Berthold; Landthaler, Míchael; Stolz, W

doi:10.1097/00008390-200208000-00015

Cited by 7 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sixty-six percent (n=29) of patients were treated with TMZ, but up to now no references have been found concerning neurotoxicity related to TMZ. As stated by Gruss et al [26], toxic leukoencephalopathy and mental deterioration after WBRT with 2.5 Gy fractions, five times a week, up to a total dose of 40 Gy and three additional boosts of 2 Gy followed by fotemustine has been reported in a patient who survived more than 2.5 years.…”

Section: Discussionmentioning

confidence: 56%

Incidence of radiation-induced leukoencephalopathy after whole brain radiotherapy in patients with brain metastases

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 56%

Incidence of radiation-induced leukoencephalopathy after whole brain radiotherapy in patients with brain metastases

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In addition, researchers have characterized the late effects of chemotherapy and radiation on the pulmonary [ 27 ], circulatory [ 28 ], and cardiac [ 29 , 30 ] systems. Reports on melanoma are uncommon and limited to older feasibility studies [ 31 ] or case reports [ 32 ]. Close, life-long medical surveillance has been recommended [ 8 ] especially for patients with choroidal melanoma, who may have more quality of life problems [ 33 , 34 ].…”

Section: Discussionmentioning

confidence: 99%

Health profiles of 996 melanoma survivors: the M. D. Anderson experience

et al. 2006

View full text Add to dashboard Cite

BackgroundThe incidence and survival of melanoma are increasing, but little is known about its long-term health effects in adult survivors.MethodsA health survey was available from 996 melanoma survivors (577 treated with surgery alone, and 391 with combined treatments). Their medical/physiologic and psychosocial responses were analyzed and compared with those of the survivors from other cancers.ResultsThe melanoma survivors were 44.8 ± 12.8 years of age at diagnosis (significantly younger than the survivors of other cancers) and 63.7 ± 12.8 years at survey. Melanoma survivors were less likely to report that cancer had affected their health than survivors of other cancers (15.8% vs. 34.9%). The 577 individuals treated with surgery alone reported arthritis/osteoporosis, cataracts, and heart problems most frequently (less often than survivors of other cancers). The 391 individuals who had undergone combined treatments reported circulation problems and kidney problems generally as often as survivors of other cancers. Health problems were not associated with number of decades since diagnosis but with age at diagnosis, treatment modality, and family relationships.ConclusionWe present information from a large cohort of long-term survivors of melanoma. As a group, they were less likely to report that cancer had affected their overall health than survivors of other cancers; a number of disease related and psychosocial factors appear to influence their health profiles.

show abstract

“…Neurocognitive effects must be a secondary endpoint in any study, as it cannot be assumed that systemic agents are devoid of adverse neurocognitive effects. For example, case reports of melanoma patients treated with fotemustine reported toxic leukoencephalopathy with progressive dementia in several patients, [137,138].…”

Section: Directions For the Futurementioning

confidence: 99%